A Phase 2 interventional study of Group-1 (15mg, OPK-88004) and Group-2 (25 mg,OPK-88004) in Benign Prostatic Hyperplasia, sponsored by OPKO Health, Inc.. Terminated at 15 sites in United States. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2021-09-16.
Sponsored by OPKO Health, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies in Prostatic Hyperplasia with a site in United States — 29 open to participants now, 48 under way, none of them phase 3. Prostatic Hyperplasia · United States.
Among the 187 studies in Prostatic Hyperplasia with a site in United States, this one is the 66th largest by enrollment of the 150 interventional ones that give a count, is one of 7 that started in 2018, is one of 27 in phase 2, and was the 110th registered.
830 studies on the registry are indexed under Prostatic Hyperplasia; 181 are open to participants now.
Browse Prostatic Hyperplasia studies →29 of the 187 studies in Prostatic Hyperplasia with a site in United States are open now. Recruiting first, the newest first:
ALPFA Medical · Sites in United States
Ages 45+ · Men only
ProVerum Medical · Sites in United States
Ages 45+ · Men only
Zenflow, Inc. · Sites in United States
Ages 18+ · Men only
Northwestern University · Sites in United States
Ages 18–100 · Men only · Healthy volunteers
Northwestern University · Sites in United States
Ages 18–100 · Men only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 45 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 35 · Phase 3 28 · Phase 4 16
First in 1988; this study’s year is marked. 7 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 114 is above the median of 94 across 629 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 83 across the 150 interventional studies, 208 across the 36 observational. Of the 119 that completed or were terminated, 58 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
98 of 187 have an industry lead sponsor. The 10 most frequent:
OPKO Health, Inc. is the lead sponsor of 49 studies on the registry; 2 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.
OPKO Health, Inc. has 1 study filed under Prostatic Hyperplasia — fewer than ten, so there is no comparison to draw.
14 of the studies in Prostatic Hyperplasia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04288427Beth Israel Deaconess Medical Center5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy | 2026-12-30 |
| NCT05400980Prodeon Medical, IncExpander-2 Trial: Randomized Study to Evaluate Safety & Efficacy of the Urocross® Expander System & Retrieval Sheath | 2027-01 |
| NCT06224218University of Illinois at ChicagoProstate Single Port & Laser Enucleation Comparison Trial | 2027-01-15 |
| NCT06560476Urotronic Inc.OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH | 2027-03-30 |
| NCT05898932Northwestern UniversityEnhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes | 2027-04 |
Add all 14 to your calendar (.ics) → With an account.
Among the 187 studies in Prostatic Hyperplasia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and effectiveness of different doses of OPK-88004 compared to placebo on serum PSA compared to placebo in men with benign prostatic hyperplasia (BPH).
Study SAR-202 is a phase 2 multicenter, placebo-controlled, double-blind trial to evaluate the effect of OPK-88004 doses (OPK-88004 15 mg, or OPK-88004 25 mg) on serum PSA compared to placebo in men with BPH. Approximately 115 men with BPH will be enrolled in the study, randomized 1:1:1 across three arms (placebo, OPK-88004 15 mg, or OPK-88004 25 mg). The trial will be conducted at approximately up to 35 sites within the US.
The study duration for individual subjects will be up to 24 weeks and will include three phases:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects are eligible if they meet the following criteria:
Exclusion Criteria
Patients will be excluded from study enrollment if they meet any of the following criteria at visit 1:
History of any of the following pelvic conditions:
History of any of the following cardiac/coronary conditions within 90 days:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo Group
Other: Placebo
15mg, OPK-88004
Drug: Group-1 (15mg, OPK-88004)
25,mg OPK-88004
Drug: Group-2 (25 mg,OPK-88004)
15mg, OPK-88004
Also known as: Selective Androgen Receptor Modulator
25 mg,OPK-88004
Also known as: Selective Androgen Receptor Modulator
Placebo
Also known as: Inactive
Change From Baseline in PSA (%) to Week 16
The trial will evaluate the effect of two doses of OPK-88004 (15 mg and 25 mg) daily for 16 weeks on serum PSA compared with placebo
Time frame: 16 weeks
Absolute Change in Lean Body Mass and Fat Mass From Baseline to 16 Weeks
To assess the effect of OPK-88004 on body composition by DXA, specifically Lean Body Mass (LBM) and fat mass
Time frame: 16 weeks
To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Peak Flow Rate (Qmax)
Analysis peak flow rate of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16
Time frame: 16 weeks
To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Mean Flow Rate (Qave)
Analysis mean flow rate of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16
Time frame: 16 weeks
To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter-voided Volume (Vcomp)
Analysis voided of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16
Time frame: 16 weeks
To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Postvoid Residual Volume (PVR)
Analysis postvoid residual volume of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16
Time frame: 16 weeks
International Prostate Symptom Score- IPSS
To evaluate the effects of OPK-88004 on the symptoms of BPH as determined by International prostate symptom score (IPSS score), Total IPSS score as measured by the sum of questions 1 through 7, the IPSS Irritative Domain (sum of questions 2, 4 and 7), and the IPSS Obstructive Domain (sum of questions 1, 3, 5 and 6)IPSS QoL question (IPSS question 8). Mild (symptoms score less than or equal to 7), moderate (symptoms score range 8-19), severe (symptom score 20-35)
Time frame: 16 weeks
| Milestone | Placebo | OPK-88004 15 mg | OPK-88004 25 mg |
|---|---|---|---|
| Started | 36 | 40 | 38 |
| Completed | 28 | 23 | 23 |
| Not completed | 8 | 17 | 15 |
| Withdrew: Sponsor's decision | 6 | 9 | 7 |
| Withdrew: Adverse event | 1 | 4 | 4 |
| Withdrew: Withdrawal by subject | 1 | 2 | 2 |
| Withdrew: Protocol violation | 0 | 2 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
The trial will evaluate the effect of two doses of OPK-88004 (15 mg and 25 mg) daily for 16 weeks on serum PSA compared with placebo
| Percentage of serum PSA change | Other | Drug Group 1 | Drug Group 2 |
|---|---|---|---|
| Change From Baseline in PSA (%) to Week 16 | -2.96 ± 5.198 | -1.48 ± 5.569 | -15.44 ± 5.509 |
To assess the effect of OPK-88004 on body composition by DXA, specifically Lean Body Mass (LBM) and fat mass
| gram | Other | Drug Group 1 | Drug Group 2 |
|---|---|---|---|
| Change from Baseline in Lean Body Mass (g) to Week 16 | 37.8 ± 439.62 | 1610.3 ± 489.45 | 1961.6 ± 522.58 |
| Change from Baseline in Fat Mass (g) to Week 16 | -198.2 ± 326.84 | -1468.7 ± 373.06 | -1491.3 ± 388.98 |
Analysis peak flow rate of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16
| millilitre/second | Other | Drug Group 1 | Drug Group 2 |
|---|---|---|---|
| To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Peak Flow Rate (Qmax) | 4.26 ± 3.810 | 0.61 ± 4.072 | 1.08 ± 4.043 |
Analysis mean flow rate of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16
| millilitre/second | Other | Drug Group 1 | Drug Group 2 |
|---|---|---|---|
| To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Mean Flow Rate (Qave) | -0.40 ± 0.475 | -0.30 ± 0.509 | 0.15 ± 0.505 |
Analysis voided of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16
| millilitre | Other | Drug Group 1 | Drug Group 2 |
|---|---|---|---|
| To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter-voided Volume (Vcomp) | -49.12 ± 21.294 | -2.28 ± 22.501 | -29.12 ± 22.714 |
Analysis postvoid residual volume of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16
| millilitre | Other | Drug Group 1 | Drug Group 2 |
|---|---|---|---|
| To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Postvoid Residual Volume (PVR) | -0.08 ± 10.365 | 17.63 ± 11.325 | -15.19 ± 10.925 |
To evaluate the effects of OPK-88004 on the symptoms of BPH as determined by International prostate symptom score (IPSS score), Total IPSS score as measured by the sum of questions 1 through 7, the IPSS Irritative Domain (sum of questions 2, 4 and 7), and the IPSS Obstructive Domain (sum of questions 1, 3, 5 and 6)IPSS QoL question (IPSS question 8). Mild (symptoms score less than or equal to 7), moderate (symptoms score range 8-19), severe (symptom score 20-35)
| Total IPSS score | Other | Drug Group 1 | Drug Group 2 |
|---|---|---|---|
| International Prostate Symptom Score- IPSS | 14.0 ± 7.70 | 12.8 ± 6.21 | 14.2 ± 7.28 |
Collected over 24 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Other | 0/36 (0%) | 0/36 (0%) | 5/36 (13.9%) |
| Drug Group 1 | 0/40 (0%) | 0/40 (0%) | 25/40 (62.5%) |
| Drug Group 2 | 0/38 (0%) | 2/38 (5.3%) | 30/38 (78.9%) |
| Event | Other | Drug Group 1 | Drug Group 2 |
|---|---|---|---|
| Coronary artery diseaseCardiac disorders | 0/36 | 0/40 | 1/38 |
| Bile duct obstructionHepatobiliary disorders | 0/36 | 0/40 | 1/38 |
| CholangitisHepatobiliary disorders | 0/36 | 0/40 | 1/38 |
| Event | Other | Drug Group 1 | Drug Group 2 |
|---|---|---|---|
| Blood testosterone decreasedInvestigations | 0/36 | 7/40 | 5/38 |
| High density lipoprotein decreasedInvestigations | 0/36 | 1/40 | 4/38 |
| Upper respiratory tract infectionInfections and infestations | 0/36 | 2/40 | 3/38 |
| Low density lipoprotein increasedInvestigations | 0/36 | 3/40 | 3/38 |
| Transaminases increasedInvestigations | 1/36 | 2/40 | 3/38 |
| Blood testosterone free decreasedInvestigations | 0/36 | 1/40 | 3/38 |
| Sperm concentration decreasedInvestigations | 0/36 | 1/40 | 3/38 |
| Prostatic specific antigen increasedInvestigations | 0/36 | 3/40 | 2/38 |
| Alanine aminotransferase increasedInvestigations | 0/36 | 3/40 | 1/38 |
| Aspartate aminotransferase increasedInvestigations | 0/36 | 3/40 | 1/38 |
| Age, Continuous(Year) | Other | Drug Group 1 | Drug Group 2 | Total |
|---|---|---|---|---|
| Mean | 64.1 ± 6.52 | 64.5 ± 5.77 | 65.3 ± 6.01 | 64.6 ± 6.06 |
| Sex: Female, Male(Participants) | Other | Drug Group 1 | Drug Group 2 | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 36 | 40 | 38 | 114 |
| Ethnicity (NIH/OMB)(Participants) | Other | Drug Group 1 | Drug Group 2 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 7 | 3 | 5 | 15 |
| Not Hispanic or Latino | 29 | 37 | 33 | 99 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Weight (kilogram)(Kilogram) | Other | Drug Group 1 | Drug Group 2 | Total |
|---|---|---|---|---|
| Mean | 94.97 ± 16.937 | 95.31 ± 19.128 | 91.35 ± 13.564 | 93.88 ± 16.692 |
| Body mass index (kilogram/meter^2)(Kilogram/meter^2) | Other | Drug Group 1 | Drug Group 2 | Total |
|---|---|---|---|---|
| Mean | 30.17 ± 5.114 | 30.37 ± 5.286 | 29.36 ± 3.442 | 29.97 ± 4.671 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2018 to primary completion in Apr 2019, 13 months.
Results were first posted in Jul 2021, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.